UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

Gastroenterology (New York, N.Y. 1943), 2019-04, Vol.156 (5), p.1392-1403.e7

2019

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

PloS one, 2018-10, Vol.13 (10), p.e0204974

2018

Volltextzugriff (PDF)

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Journal of hepatology, 2024-09, Vol.81 (3), p.404-414

2024

Volltextzugriff (PDF)

Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment

Journal of clinical pharmacology, 2023-06, Vol.63 (6), p.732-741

2023

Volltextzugriff (PDF)

Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Clinical pharmacokinetics, 2017-05, Vol.56 (5), p.525-536

2017

Volltextzugriff (PDF)

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

The Journal of infectious diseases, 2019-01, Vol.219 (2), p.177-185

2019

Volltextzugriff (PDF)

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

Journal of antimicrobial chemotherapy, 2022-03, Vol.77 (4), p.1102-1110

2022

Volltextzugriff (PDF)

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

Antiviral therapy, 2022-06, Vol.27 (3), p.13596535221093856-13596535221093856

2022

Volltextzugriff (PDF)

The Cellular Pharmacology of Nucleoside- and Nucleotide-Analogue Reverse-Transcriptase Inhibitors and Its Relationship to Clinical Toxicities

Clinical infectious diseases, 2004-03, Vol.38 (5), p.743-753

2004

Volltextzugriff (PDF)

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

Journal of clinical pharmacology, 2014-08, Vol.54 (8), p.949-957

2014

Volltextzugriff (PDF)

Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Hepatology (Baltimore, Md.), 2018-12, Vol.68 (6), p.2145-2157

2018

Volltextzugriff (PDF)

Single‐ and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers

British journal of clinical pharmacology, 2018-11, Vol.84 (11), p.2663-2672

2018

Volltextzugriff (PDF)

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

Antiviral therapy, 2021-01, Vol.26 (1-2), p.13-24

2021

Volltextzugriff (PDF)

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

Clinical pharmacology in drug development, 2022-12, Vol.11 (12), p.1419-1429

2022

Volltextzugriff (PDF)

Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE)

The Pediatric infectious disease journal, 2014-09, Vol.33 (9), p.940-945

2014

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir

Journal of antimicrobial chemotherapy, 2014-10, Vol.69 (10), p.2591-2605

2014

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

Clinical pharmacokinetics, 2009-01, Vol.48 (9), p.561-574

2009

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.175-180

2023

Volltextzugriff (PDF)

Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers

Antiviral therapy, 2014-01, Vol.19 (6), p.597-606

2014

Volltextzugriff (PDF)

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

AIDS research and therapy, 2014-12, Vol.11 (1), p.39-39

2014

Volltextzugriff (PDF)

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4228-4232

2008

Volltextzugriff (PDF)

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

Clinical pharmacokinetics, 2011, Vol.50 (1), p.25-39

2011

Volltextzugriff (PDF)

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

The AAPS journal, 2019-01, Vol.21 (1), p.1-1, Article 1

2019

Volltextzugriff (PDF)

Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial

The Pediatric infectious disease journal, 2015-05, Vol.34 (5), p.e132-e137

2015

Volltextzugriff (PDF)

Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults

Antiviral therapy, 2018-01, Vol.23 (7), p.555-566

2018

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(107)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment

Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

The Cellular Pharmacology of Nucleoside- and Nucleotide-Analogue Reverse-Transcriptase Inhibitors and Its Relationship to Clinical Toxicities

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Single‐ and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE)

Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants

Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial

Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults

Suchergebnisse filtern